What you say does bother me, the thought has for years. In my mind it is balanced by the fact that both BP and the feds pay little attention to little bios unless there is a clean, powerful set of Ph3 findings (or astounding Ph2 findings in an area of great need and cost potential). And even then there better be lots of product available, distribution agreements and all the rest of the lesser but important aspects of a successful pharma product introduction; all best delivered by a solid agreement with a company at least the size of AS.
News 
Market Data 
Discover 
